On Monday, Iterum Therapeutics Plc (NASDAQ: ITRM) opened lower -6.44% from the last session, before settling in for the closing price of $0.45. Price fluctuations for ITRM have ranged from $0.36 to $2.10 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 58.85% over the last five years. Company’s average yearly earnings per share was noted 25.84% at the time writing. With a float of $52.37 million, this company’s outstanding shares have now reached $52.79 million.
Iterum Therapeutics Plc (ITRM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Iterum Therapeutics Plc is 0.79%, while institutional ownership is 2.52%. The most recent insider transaction that took place on Nov 18 ’25, was worth 2,191. In this transaction Director of this company bought 6,000 shares at a rate of $0.37, taking the stock ownership to the 241,001 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Director bought 15,000 for $0.72, making the entire transaction worth $10,854. This insider now owns 235,001 shares in total.
Iterum Therapeutics Plc (ITRM) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.12 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.24) by 0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.77% during the next five years compared to 58.85% growth over the previous five years of trading.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Check out the current performance indicators for Iterum Therapeutics Plc (ITRM). In the past quarter, the stock posted a quick ratio of 1.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 56.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Analysing the last 5-days average volume posted by the [Iterum Therapeutics Plc, ITRM], we can find that recorded value of 0.43 million was lower than the volume posted last year of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 31.49%.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 10.79%, which indicates a significant decrease from 14.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0430 in the past 14 days, which was lower than the 0.0505 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5743, while its 200-day Moving Average is $0.8706. Now, the first resistance to watch is $0.4484. This is followed by the second major resistance level at $0.4758. The third major resistance level sits at $0.4900. If the price goes on to break the first support level at $0.4068, it is likely to go to the next support level at $0.3926. Now, if the price goes above the second support level, the third support stands at $0.3652.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
There are currently 52,788K shares outstanding in the company with a market cap of 22.22 million. Presently, the company’s annual sales total 0 K according to its annual income of -24,770 K. Last quarter, the company’s sales amounted to 390 K and its income totaled -8,980 K.
